The 2026 Global Delphi Consensus on Acne and the Microbiome backs microbiome-targeted treatments for acne management with 100% expert agreement. For adults with persistent acne, the buying question is whether a probiotic or microbiome-friendly product treats acne or only supports appearance. A Delphi consensus is structured expert voting across rounds to reach agreement. The panel integrated international expertise on prevention and therapeutic strategies, as reported by MDPI Pharmaceuticals in the consensus paper.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the experts agreed on
- Why persistent adult acne changes the stakes
- Why expert agreement is not product proof
- How to read microbiome-friendly labels
What the experts agreed on
The panel unanimously agreed at 100% that microbiome-targeted treatments should be adopted for acne management. It also reached 89% agreement that the microbiome influences acne severity and that the gut-skin axis directly affects acne, according to the full consensus PDF.
The same 89% agreement covered probiotics as offering potential benefits. It also covered prebiotics, probiotics and postbiotics as belonging in acne therapy. In plain terms, microbes on skin and in the gut are seen as active players, not background noise.
Why persistent adult acne changes the stakes
Persistent acne often affects women over 25. A UK community study estimated facial acne in 14% of women aged 26-44.
A large international study found 50.8% reported persistent acne on most days, with 59.4% reporting scarring. Long duration plus scarring risk makes product choice more than cosmetic. Adult readers need options that fit ongoing care, not quick fixes.
Why expert agreement is not product proof
Delphi consensus is structured expert opinion, not proof that a specific cream, cleanser or supplement works. U.S. FTC health-claim guidance requires competent and reliable scientific evidence, generally randomized controlled human trials, as explained in FTC health-claim guidance.
That gap matters for shopping. Strong expert interest in probiotics supports research and clinical use. It does not make every "balances your microbiome" claim proven for your acne.
How to read microbiome-friendly labels
FDA policy treats cosmetics that claim to mitigate disease such as acne as drugs requiring FDA review and approval. Cosmetics may claim only cleansing, beautifying or altering appearance, as summarized in an FDA consumer update.
A 2026 Medscape Dermatology review found dermocosmetics usable as monotherapy for mild acne and adjunctively for mild-to-moderate acne. It reported better barrier function, sebum control and fewer inflammatory and noninflammatory lesions. "Microbiome-friendly" language must therefore avoid unapproved treat or cure wording.
- Check the verb: cleanses, moisturizes and improves look are cosmetic claims.
- Flag the verb: treats, cures, clears acne or kills acne bacteria are drug claims.
- Match severity: mild breakouts may fit dermocosmetic care, while persistent, painful or scarring acne needs a clinician plan.
- Keep the product as adjunct when using prescription therapy, unless your clinician advises otherwise.
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Product-Claim Questions for Adults With Persistent Acne
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Product-Claim Questions for Adults With Persistent Acne
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Product-Claim Questions for Adults With Persistent Acne